White Glove and Cold Chain Services for Advanced Healthcare Solutions #WeCare
Growth in biopharma and advanced treatments are enabling healthcare providers to take on previously untreatable diseases. This trend is resulting in better health outcomes, but also places additional demands on supply chain operations. From pre-clinical to commercial, there is a need for expanded cold chain networks, colder temperature regimes and higher service levels.
Our global cold chain network, express delivery and end-to-end monitoring capability make DHL a trusted partner to manage these changing demands. We specialize in getting your investigational medicinal product (IMP) out of the lab through to scaling to new commercial markets with precision and speed.
DHL Life Sciences & Healthcare is committed to enabling you to address industry-specific challenges while driving growth and innovation, with a wide range of compliant solutions, including specialized white glove delivery with cryogenic temperature control, seamless IMP movement and end-to-end cold chain management for high-volume pharma.
Vital Signs: Symptoms of a Healthcare Sector in Transition
Biopharmaceutical products will comprise 41% of the global pharmaceutical market by 2028, up from 33% in 2020.
CELL AND GENE THERAPIES
DEMAND FOR CELL AND GENE THERAPIES IS VOLATILE AND UNPREDICTABLE, BUT DELIVERY MUST BE FAST, ACCURATE AND TIGHTLY CONTROLLED.
More than 2,400
new biopharma products are currently undergoing clinical trials
MANAGING COMPLEX SUPPLY CHAINS IN A REGULATORY COMPLIANT, COST-EFFECTIVE WAY WILL DEMAND RIGOROUS END-TO-END CONTROL.